Spondyloarthritis & psoriatic arthritis
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
Authors' conclusion
The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.
Study context
- Population
- Patients with psoriatic arthritis (PsA); articles published since the 2019 update until 28 December 2022 (Medline, EMBASE, Cochrane CENTRAL)38 articles (30 trials) analysed
- Comparison
- csDMARDs, bDMARDs and Janus Kinase inhibitors (JAKi) in PsA
- Outcome
- Efficacy
Methodological detailsno meta-analyses performed, efficacy from trials; safety also from observational data
- No meta-analyses performed
- Efficacy from trials; safety also from observational data
Pooled result
As reported in the abstract
Articles screened for efficacy
3946
Articles analysed for efficacy (trials)
38
30
Safety
Safety (GC, TNFi, IL-17i, JAKi, IL-12/23i, PDE4i)
- Abstracts screened for safety
- 2055
- Articles analysed for safety
- 24
- Observational studies
- 15
- Long-term follow-ups of trials
- 9
- Safety indicators generally coherent with the previous systematic literature research (SLR) in 2019
Original publication
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. Published 15 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →